Dmytro Kharkov

Will Hims & Hers stock break $29.01 resistance as multiple securities fraud class actions filed?

Will Hims & Hers stock break $29.01 resistance as multiple securities fraud class actions filed?
Hims & Hers up 0.84% today

Hims & Hers (HIMS) stock is trading at $28.68, registering a modest daily increase. The price sits below its key short- and medium-term moving averages, while remaining above levels tracked by longer-term trends.

HIMS price prediction
24H 1.5%
$26.39
48H 1.42%
$26.37
7D 3.5%
$26.91
1M -15.73%
$21.91
3M -36.65%
$16.47
6M -62.38%
$9.78
12M -44.42%
$14.45
Current price: $26 1.94 8.06%
Closed 11/06
Daily range 24.57 Arrow from to Icon 26.23
Weekly range 22.95 Arrow from to Icon 28.61
Loading...

Highlights

  • The Federal Trade Commission filed a lawsuit on July 29, 2026, alleging Hims & Hers engaged in improper billing and shared sensitive consumer health data.
  • Hims & Hers now faces additional securities class action lawsuits and ongoing operational issues with increased credit card disputes in its weight-loss subscription segment.
  • HIMS stock trades below key short- and medium-term moving averages, with negative momentum indictors and an expected price range of $26.97 to $30.39 favoring further downside.

Legal pressures mount as FTC lawsuit and billing disputes intensify

A major regulatory event for Hims & Hers emerged on July 29, 2026, when the Federal Trade Commission filed a lawsuit alleging the company engaged in improper billing and shared sensitive consumer health data, according to Globenewswire. This action created significant legal and reputational risk, leading to further securities class action lawsuits and deadline notifications for shareholders, as highlighted by Prnewswire. Operational headwinds persist, with Investing.com reporting increased credit card disputes in the weight-loss subscription segment, further reinforcing the ongoing regulatory and legal pressures on the business.

Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Selling momentum dominates as resistance holds below short-term averages

On the hourly chart, HIMS is trading below both the MA-20 and MA-50 but remains above the longer-term MA-200. The Ichimoku Kijun line at $29.01 serves as near-term resistance, with price action currently capped beneath this level. Key support stands at $26.97, while resistance sits at $30.39. Among technical indicators, MACD is at Strong Sell, ADX signals a neutral but unstable trend, and both RSI and CCI reflect ongoing selling pressure. Stochastic RSI and the Awesome Oscillator remain neutral, while Bull/Bear Power shows intraday dominance by sellers.

Downside risk prevails amid limited chance for breakout

Looking ahead to the next two to three trading days, HIMS is projected to fluctuate within a volatility band of $26.97 to $30.39. The most probable outcome is continued sideways movement inside this range, with the probability of a meaningful advance considered very low and the likelihood of a decline viewed as very high. Should HIMS break above the $29.01 resistance, a bullish scenario may unfold, while a drop below $26.97 would signal increased downside risk.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers navigating a period of heightened legal and reputational scrutiny after the recent FTC lawsuit. The analyst notes that while the stock remains technically contained in a volatile range, sentiment and fundamentals remain pressured by regulatory and operational setbacks. Karapetjanc remains cautiously constructive, highlighting the company's ability to hold above long-term supports despite headline risks. "If HIMS can reclaim $29.01 and stabilize, we may see renewed optimism from investors even as legal overhang persists."

Earlier, analysts noted that persistent technical weakness in Hims & Hers shares outweighed the benefits of its international expansion, warranting caution. The latest regulatory and legal headwinds add a significant downside risk, making $26.97 a critical level for traders to monitor in the near term.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.